Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Entrada Therapeutics, Inc. - Common Stock
(NQ:
TRDA
)
4.370
-0.410 (-8.58%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Entrada Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
October 14, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
October 14, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
September 10, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
August 05, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
June 02, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
May 17, 2026
From
Schall Law
Via
GlobeNewswire
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 07, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 07, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 06, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
February 17, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 04, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
January 08, 2026
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
November 06, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 28, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
September 05, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 03, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
May 28, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports First Quarter 2025 Financial Results
May 08, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
